{
  "paper_metadata": {
    "pmid": "31452023",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted genetic variant information for the TTR gene, including penetrance data."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.364G>A",
      "protein_notation": "p.Val122Ile",
      "genomic_position": null,
      "clinical_significance": "likely pathogenic",
      "patients": {
        "count": 1,
        "demographics": "African-American descent, approximately 4% of this population is heterozygous for this variant",
        "phenotype": "cardiac amyloidosis with onset of heart failure signs and symptoms typically after 60 years of age"
      },
      "penetrance_data": {
        "total_carriers_observed": 1,
        "affected_count": 1,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case_1",
          "age_at_evaluation": null,
          "age_at_onset": 60,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "cardiac amyloidosis",
          "evidence_sentence": "This mutation results in cardiac amyloidosis with onset of heart failure signs and symptoms typically after 60 years of age."
        }
      ],
      "functional_data": {
        "summary": "The V122I variant is associated with increased risk for clinical manifestations of heart failure.",
        "assays": []
      },
      "segregation_data": "This variant is prevalent in the African-American population, suggesting a potential familial component.",
      "population_frequency": "Approximately 4% in the African-American population.",
      "evidence_level": "Moderate evidence based on population frequency and clinical presentation.",
      "source_location": "Main Text, paragraph discussing the V122I variant.",
      "additional_notes": "The variant is not commonly associated with significant peripheral neuropathy manifestations.",
      "key_quotes": [
        "This mutation results in cardiac amyloidosis with onset of heart failure signs and symptoms typically after 60 years of age.",
        "Observational data demonstrate that carriers of this mutation have greater risk for clinical manifestations of heart failure but not increased age-adjusted mortality."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data for the TTR gene was extracted successfully."
  }
}